Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple rising subcutaneous doses of BI 3006337 in healthy Japanese males
jRCT2031230638Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing BI 3006337 arm with Placebo arm (2 arms). Primary endpoint: Drug-related adverse events. Started Apr 2024; status: active, not recruiting.
02
Drugs
YH25724
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031230638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230638.